1887

Abstract

α-Melanocyte-stimulating hormone (α-MSH) is a tridecapeptide derived from pro-opiomelanocortin that exhibits potent anti-inflammatory properties by regulating the production of inflammatory mediators. This peptide has been well established in several inflammatory models, including inflammatory bowel disease (IBD). However, its extremely short duration in vivo limits its clinical application. To address this limitation, Bifidobacterium was used here as a carrier to deliver α-MSH. We utilized α-MSH-engineered Bifidobacterium against IBD, which is closely linked to immune and intestinal microbiota dysfunction. First, we constructed a Bifidobacterium longum secreting α-MSH (B. longum-α-MSH). We then tested the recombinant α-MSH expression and determined its bioactivity in HT-29 cells. To assess its effectiveness, B. longum-α-MSH was used against an ulcerative colitis (UC) model in rats induced by dextran sulfate sodium. The data showed that α-MSH expression in B. longum-α-MSH was effective, and its biological activity was similar to the synthesized one. This UC model experiment indicated that B. longum-α-MSH successfully colonized the intestinal gut, expressed bioactive α-MSH and had a significant anti-inflammatory effect. The results demonstrate the feasibility of preventing IBD by using B. longum-α-MSH.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.000197
2016-02-01
2019-10-19
Loading full text...

Full text loading...

/deliver/fulltext/jmm/65/2/160.html?itemId=/content/journal/jmm/10.1099/jmm.0.000197&mimeType=html&fmt=ahah

References

  1. Arena M. P., Russo P., Capozzi V., López P., Fiocco D., Spano G.. ( 2014;). Probiotic abilities of riboflavin-overproducing Lactobacillus strains: a novel promising application of probiotics. Appl Microbiol Biotechnol 98: 7569–7581 [CrossRef] [PubMed].
    [Google Scholar]
  2. Bai A., Peng Z.. ( 2010;). Biological therapies of inflammatory bowel disease. Immunotherapy 2: 727–742 [CrossRef] [PubMed].
    [Google Scholar]
  3. Braat H., Peppelenbosch M. P., Hommes D. W.. ( 2003;). Interleukin-10-based therapy for inflammatory bowel disease. Expert Opin Biol Ther 3: 725–731 [CrossRef] [PubMed].
    [Google Scholar]
  4. Brzoska T., Luger T. A., Maaser C., Abels C., Böhm M.. ( 2008;). α-Melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases. Endocr Rev 29: 581–602 [CrossRef] [PubMed].
    [Google Scholar]
  5. Brzoska T., Böhm M., Lügering A., Loser K., Luger T. A.. ( 2010;). Terminal signal: anti-inflammatory effects of α-melanocyte-stimulating hormone related peptides beyond the pharmacophore. Adv Exp Med Biol 681: 107–116 [CrossRef] [PubMed].
    [Google Scholar]
  6. Carniglia L., Durand D., Caruso C., Lasaga M.. ( 2013;). Effect of NDP-α-MSH on PPAR-γ and -β expression and anti-inflammatory cytokine release in rat astrocytes and microglia. PLoS One 8: e57313 [CrossRef] [PubMed].
    [Google Scholar]
  7. Cekic C., Arabul M., Alper E., Pakoz Z. B., Saritas E., Yuksel, Ünsal B.. ( 2014;). Evaluation of the relationship between serum ghrelin, C-reactive protein and interleukin-6 levels, and disease activity in inflammatory bowel diseases. Hepatogastroenterology 61: 1196–1200.
    [Google Scholar]
  8. Chenoll E., Rivero M., Codoñer F. M., Martinez-Blanch J. F., Ramón D., Genovés S., Moreno Muñoz J. A.. ( 2015;). Complete genome sequence of Bifidobacterium longum subsp. infantis strain CECT 7210, a probiotic strain active against rotavirus infections. Genome Announc 3: e00105–e00115 [CrossRef] [PubMed].
    [Google Scholar]
  9. Chokshi N. K., Guner Y. S., Hunter C. J., Upperman J. S., Grishin A., Ford H. R.. ( 2008;). The role of nitric oxide in intestinal epithelial injury and restitution in neonatal necrotizing enterocolitis. Semin Perinatol 32: 92–99 [CrossRef] [PubMed].
    [Google Scholar]
  10. Cohen L. B., Nanau R. M., Delzor F., Neuman M. G.. ( 2014;). Biologic therapies in inflammatory bowel disease. Transl Res 163: 533–556 [CrossRef] [PubMed].
    [Google Scholar]
  11. Delroisse J. M., Boulvin A. L., Parmentier I., Dauphin R. D., Vandenbol M., Portetelle D.. ( 2008;). Quantification of Bifidobacterium spp. and Lactobacillus spp. in rat fecal samples by real-time PCR. Microbiol Res 163: 663–670 [CrossRef] [PubMed].
    [Google Scholar]
  12. Fabrikant J., Touloei K., Brown S. M.. ( 2013;). A review and update on melanocyte stimulating hormone therapy: afamelanotide. J Drugs Dermatol 12: 775–779 [PubMed].
    [Google Scholar]
  13. Fan T., Chen C., Guo H., Xu J., Zhang J., Zhu X., Yang Y., Zhou Z., Li L., Huang Y.. ( 2014;). Design and evaluation of solid lipid nanoparticles modified with peptide ligand for oral delivery of protein drugs. Eur J Pharm Biopharm 88: 518–528 [CrossRef] [PubMed].
    [Google Scholar]
  14. Gambero A., Maróstica M., Abdalla Saad M. J., Pedrazzoli J. Jr.. ( 2007;). Mesenteric adipose tissue alterations resulting from experimental reactivated colitis. Inflamm Bowel Dis 13: 1357–1364 [CrossRef] [PubMed].
    [Google Scholar]
  15. He Z., Hua J., Song Z.. ( 2014;). Mesenchymal stem cells ameliorate tissue injury via secretion of tumor necrosis factor-α stimulated protein/gene 6. Stem Cells Int 2014: 761091 [CrossRef] [PubMed].
    [Google Scholar]
  16. Hensel K. O., Boland V., Postberg J., Zilbauer M., Heuschkel R., Vogel S., Gödde D., Wirth S., Jenke A. C.. ( 2014;). Differential expression of mucosal trefoil factors and mucins in pediatric inflammatory bowel diseases. Sci Rep 4: 7343 [CrossRef] [PubMed].
    [Google Scholar]
  17. Huang H., Koelle P., Fendler M., Schröttle A., Czihal M., Hoffmann U., Conrad M., Kuhlencordt P. J.. ( 2014;). Induction of inducible nitric oxide synthase (iNOS) expression by oxLDL inhibits macrophage derived foam cell migration. Atherosclerosis 235: 213–222 [CrossRef] [PubMed].
    [Google Scholar]
  18. Kaser A., Zeissig S., Blumberg R. S.. ( 2010;). Inflammatory bowel disease. Annu Rev Immunol 28: 573–621 [CrossRef] [PubMed].
    [Google Scholar]
  19. Kim N., Kunisawa J., Kweon M. N., Eog Ji G., Kiyono H.. ( 2007;). Oral feeding of Bifidobacterium bifidum (BGN4) prevents CD4+ CD45RBhigh T cell-mediated inflammatory bowel disease by inhibition of disordered T cell activation. Clin Immunol 123: 30–39 [CrossRef] [PubMed].
    [Google Scholar]
  20. Krieglstein C. F., Anthoni C., Cerwinka W. H., Stokes K. Y., Russell J., Grisham M. B., Granger D. N.. ( 2007;). Role of blood- and tissue-associated inducible nitric-oxide synthase in colonic inflammation. Am J Pathol 170: 490–496 [CrossRef] [PubMed].
    [Google Scholar]
  21. Kuehbacher T., Rehman A., Lepage P., Hellmig S., Fölsch U. R., Schreiber S., Ott S. J.. ( 2008;). Intestinal TM7 bacterial phylogenies in active inflammatory bowel disease. J Med Microbiol 57: 1569–1576 [CrossRef] [PubMed].
    [Google Scholar]
  22. Lu X., Yao Y., Zhang W.. ( 2007;). A novel sodium bis(2-ethylhexyl) sulfosuccinate-PAGE system suitable for the separation of small peptides. Electrophoresis 28: 3174–3177 [CrossRef] [PubMed].
    [Google Scholar]
  23. Macfarlane S., Furrie E., Cummings J. H., Macfarlane G. T.. ( 2004;). Chemotaxonomic analysis of bacterial populations colonizing the rectal mucosa in patients with ulcerative colitis. Clin Infect Dis 38: 1690–1699 [CrossRef] [PubMed].
    [Google Scholar]
  24. Martinez F. A., Balciunas E. M., Converti A., Cotter P. D., de Souza Oliveira R. P.. ( 2013;). Bacteriocin production by Bifidobacterium spp. A review. Biotechnol Adv 31: 482–488 [CrossRef] [PubMed].
    [Google Scholar]
  25. Medina M., Izquierdo E., Ennahar S., Sanz Y.. ( 2007;). Differential immunomodulatory properties of Bifidobacterium logum strains: relevance to probiotic selection and clinical applications. Clin Exp Immunol 150: 531–538 [CrossRef] [PubMed].
    [Google Scholar]
  26. Meile L., Le Blay G., Thierry A.. ( 2008;). Safety assessment of dairy microorganisms: Propionibacterium and Bifidobacterium. Int J Food Microbiol 126: 316–320 [CrossRef] [PubMed].
    [Google Scholar]
  27. Meyer L., Simian D., Lubascher J., Acuña R., Figueroa C., Silva G., Brahm J., Quera R.. ( 2015;). [Adverse events associated with the treatment of inflammatory bowel disease]. Rev Med Chil 143: 7–13 (in Spanish) [CrossRef] [PubMed].
    [Google Scholar]
  28. Möller B., Villiger P. M.. ( 2006;). Inhibition of IL-1, IL-6, and TNF-α in immune-mediated inflammatory diseases. Springer Semin Immunopathol 27: 391–408 [CrossRef] [PubMed].
    [Google Scholar]
  29. Moraes M. N., dos Santos L. R., Mezzalira N., Poletini M. O., Castrucci A. M.. ( 2014;). Regulation of melanopsins and Per1 by α-MSH and melatonin in photosensitive Xenopus laevis melanophores. BioMed Res Int 2014: 654710 [PubMed].[CrossRef]
    [Google Scholar]
  30. Park M. S., Kwon B., Shim J. J., Huh C. S., Ji G. E.. ( 2008;). Heterologous expression of cholesterol oxidase in Bifidobacterium longum under the control of 16S rRNA gene promoter of bifidobacteria. Biotechnol Lett 30: 165–172 [CrossRef] [PubMed].
    [Google Scholar]
  31. Park J. H., Kwon J. G., Kim S. J., Song D. K., Lee S. G., Kim E. S., Cho K. B., Jang B. I., Kim D. H., other authors. ( 2015;). Alterations of colonic contractility in an interleukin-10 knockout mouse model of inflammatory bowel disease. J Neurogastroenterol Motil 21: 51–61 [CrossRef] [PubMed].
    [Google Scholar]
  32. Philippe D., Heupel E., Blum-Sperisen S., Riedel C. U.. ( 2011;). Treatment with Bifidobacterium bifidum 17 partially protects mice from Th1-driven inflammation in a chemically induced model of colitis. Int J Food Microbiol 149: 45–49 [CrossRef] [PubMed].
    [Google Scholar]
  33. Potas J. R., Haque F., Maclean F. L., Nisbet D. R.. ( 2015;). Interleukin-10 conjugated electrospun polycaprolactone (PCL) nanofibre scaffolds for promoting alternatively activated (M2) macrophages around the peripheral nerve in vivo. J Immunol Methods 420: 38–49 [CrossRef] [PubMed].
    [Google Scholar]
  34. Quigley E. M.. ( 2011;). Therapies aimed at the gut microbiota and inflammation: antibiotics, prebiotics, probiotics, synbiotics, anti-inflammatory therapies. Gastroenterol Clin North Am 40: 207–222 [CrossRef] [PubMed].
    [Google Scholar]
  35. Reyes Escogido M. L., De León Rodríguez A., Barba de la Rosa A. P.. ( 2007;). A novel binary expression vector for production of human IL-10 in Escherichia coli and Bifidobacterium longum. Biotechnol Lett 29: 1249–1253 [CrossRef] [PubMed].
    [Google Scholar]
  36. Sambrook J., Russell D. W.. ( 2001;). Molecular Cloning: a Laboratory Manual New York: Cold Spring Harbor Laboratory Press;.
    [Google Scholar]
  37. Sanchez-Munoz F., Dominguez-Lopez A., Yamamoto-Furusho J. K.. ( 2008;). Role of cytokines in inflammatory bowel disease. World J Gastroenterol 14: 4280–4288 [CrossRef] [PubMed].
    [Google Scholar]
  38. Scheuch G., Siekmeier R.. ( 2007;). Novel approaches to enhance pulmonary delivery of proteins and peptides. J Physiol Pharmacol 58: (Suppl 5), 615–625 [PubMed].
    [Google Scholar]
  39. Singh R., Singh S., Lillard J. W. Jr.. ( 2008;). Past, present, and future technologies for oral delivery of therapeutic proteins. J Pharm Sci 97: 2497–2523 [CrossRef] [PubMed].
    [Google Scholar]
  40. Strober W., Fuss I., Mannon P.. ( 2007;). The fundamental basis of inflammatory bowel disease. J Clin Invest 117: 514–521 [CrossRef] [PubMed].
    [Google Scholar]
  41. Temp F. R., Santos A. C., Marafiga J. R., Jesse A. C., Lenz Q. F., Oliveira S. M., Guerra G. P., Scimonelli T. N., Mello C. F.. ( 2013;). Alpha melanocyte stimulating hormone (α-MSH) does not modify pentylenetetrazol- and pilocarpine-induced seizures. Life Sci 93: 723–731 [CrossRef] [PubMed].
    [Google Scholar]
  42. Tena D., Losa C., Medina M. J., Sáez-Nieto J. A.. ( 2014;). Peritonitis caused by Bifidobacterium longum: case report and literature review. Anaerobe 27: 27–30 [CrossRef] [PubMed].
    [Google Scholar]
  43. Tennoune N., Chan P., Breton J., Legrand R., Chabane Y. N., Akkermann K., Järv A., Ouelaa W., Takagi K., other authors. ( 2014;). Bacterial ClpB heat-shock protein, an antigen-mimetic of the anorexigenic peptide α-MSH, at the origin of eating disorders. Transl Psychiatry 4: e458 [CrossRef] [PubMed].
    [Google Scholar]
  44. Triantafyllidi A., Xanthos T., Papalois A., Triantafillidis J. K.. ( 2015;). Herbal and plant therapy in patients with inflammatory bowel disease. Ann Gastroenterol 28: 210–220 [PubMed].
    [Google Scholar]
  45. Tsai Y. T., Cheng P. C., Pan T. M.. ( 2014;). Anti-obesity effects of gut microbiota are associated with lactic acid bacteria. Appl Microbiol Biotechnol 98: 1–10 [CrossRef] [PubMed].
    [Google Scholar]
  46. Turroni F., van Sinderen D., Ventura M.. ( 2011;). Genomics and ecological overview of the genus Bifidobacterium. Int J Food Microbiol 149: 37–44 [CrossRef] [PubMed].
    [Google Scholar]
  47. Turroni F., Duranti S., Bottacini F., Guglielmetti S., Van Sinderen D., Ventura M.. ( 2014;). Bifidobacterium bifidum as an example of a specialized human gut commensal. Front Microbiol 5: 437 [CrossRef] [PubMed].
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.000197
Loading
/content/journal/jmm/10.1099/jmm.0.000197
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error